Klingenstein Fields & Co. LP Boosts Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Klingenstein Fields & Co. LP grew its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 1,083.7% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 6,806 shares of the biopharmaceutical company's stock after buying an additional 6,231 shares during the period. Klingenstein Fields & Co. LP's holdings in Regeneron Pharmaceuticals were worth $4,848,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Rakuten Securities Inc. grew its holdings in shares of Regeneron Pharmaceuticals by 380.0% during the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company's stock worth $25,000 after purchasing an additional 19 shares during the last quarter. FSA Wealth Management LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter valued at about $26,000. Fairfield Financial Advisors LTD purchased a new position in Regeneron Pharmaceuticals during the 3rd quarter worth approximately $37,000. Private Wealth Management Group LLC grew its stake in Regeneron Pharmaceuticals by 260.0% during the 4th quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company's stock worth $38,000 after buying an additional 39 shares during the last quarter. Finally, Truvestments Capital LLC acquired a new position in Regeneron Pharmaceuticals during the third quarter worth approximately $39,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the company. Leerink Partnrs raised Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Wednesday, February 5th. Barclays lowered their price objective on shares of Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an "overweight" rating on the stock in a research report on Friday, November 1st. Wells Fargo & Company reduced their target price on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an "overweight" rating for the company in a report on Friday, January 10th. Royal Bank of Canada lowered their price target on Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an "outperform" rating on the stock in a report on Friday, November 1st. Finally, StockNews.com downgraded Regeneron Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Monday, November 4th. One research analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat, Regeneron Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus target price of $973.13.

Regeneron Pharmaceuticals Price Performance

Shares of REGN stock traded up $6.40 during midday trading on Tuesday, reaching $680.00. 743,097 shares of the company traded hands, compared to its average volume of 945,916. The firm's 50 day simple moving average is $704.64 and its two-hundred day simple moving average is $891.91. The firm has a market cap of $74.73 billion, a PE ratio of 17.76, a price-to-earnings-growth ratio of 2.38 and a beta of 0.08. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 4.46. Regeneron Pharmaceuticals, Inc. has a 1-year low of $642.00 and a 1-year high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, topping analysts' consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The company had revenue of $3.79 billion for the quarter, compared to the consensus estimate of $3.76 billion. During the same period in the previous year, the business earned $11.86 earnings per share. Regeneron Pharmaceuticals's quarterly revenue was up 10.3% compared to the same quarter last year. On average, equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 36.67 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th will be issued a dividend of $0.88 per share. The ex-dividend date of this dividend is Thursday, February 20th. This represents a $3.52 annualized dividend and a yield of 0.52%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is currently 2.30%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.